AstraZeneca և Merck’s Lynparza could be a new tool in the fight against early-stage breast cancer, after data released ahead of the biggest oncology conference of the year showed that it significantly reduces recurrence rates in patients with BRCA genetic mutation.
David Fredrickson, executive vice president of oncology at AstraZeneca, says the company’s focus on “earlier intelligent interventions” is helping to cure many types of cancer. Pharmaceutical companies are expected to submit test data to regulators to confirm this condition.
An OlympiA study found that taking Lynparza on top of normal treatment, such as chemotherapy, surgery, and sometimes radiotherapy, was estimated to reduce the risk of a life-threatening recurrence by 42 percent. The study will be published New England Journal of Medicine: և Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting this weekend.
“Overnight, the prognosis for these women is to go from no therapy specifically targeting her type of cancer to therapy,” Fredrickson said.
AstraZeneca: innovation in oncology In recent years he has helped turn the tide in Anglo-Swedish pharmacy. Sales of oncology in the first quarter from drugs, including Lynparza, Tagrisso և Imfinzi increased by 20% year by year: Merck, a US pharmaceutical company, is pioneering immunotherapy using the immune system to target tumors with its Keytruda blockbuster drug.
Fredrickson warned that better research is needed, especially as the epidemic has been diagnosed with cancer in order to get the most out of therapies that work best when given early. Official data from the UK show that stage 1 cancer diagnoses fell by about a third in the first months of the epidemic compared to the same period last year.
“We are very concerned about the new damage caused by the epidemic, which is related to the new cancer diagnosis and test results,” he said.
Launched in 2014, Lynparza has already been successful in the later stages of breast cancer, which has spread և untreated և ovarian և pancreatic cancer. It is known as a parp inhibitor, targeting the target in the cancer DNA repair system.
About 15 percent of people with breast cancer have so-called triple-negative cancers that do not respond to other targeted treatments, many of which have one of two BRCA mutations that affect the body’s ability to suppress tumors.
Andrew Tutt, a professor at the Cancer Research Institute who chaired the trial oversight committee, says BRCA mutation tests were commonly used to determine the risk of developing cancer. But if the drug is approved for the condition, he said, oncologists should use the diagnostic to select the right patient for the doctor.
“This is a completely new way to use cancer genetics in therapeutic conditions,” he said.
Lori J .. Pierce, president of the American Society of Clinical Oncology, said the results could have a “significant impact” on treatment decisions for this subset of patients.
“OlympiA results highlight the need for genetic testing of BRCA mutations in patients at an early stage of high-risk breast cancer,” he said.
At the ASCO conference, Novartis will share the results of an experiment using a new, targeted radiotherapy known as radioligand, resistant to prostate metastatic castration cancer, which significantly improved survival rates when combined with normal treatment.
Amgen will share data on the survival of its Lumakras cancer drugs targeting KRAS – formerly known as “Harmless target” – The main tumor breaker that puts cancer cells. The drug has recently been approved by the Food and Drug Administration for patients with non-small cell lung cancer with a specific genetic mutation.